Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602224 · ClinicalTrials.gov registry record · Phase 2
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT01602224 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 220 participants.
The verdict
NCT01602224, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Bortezomib
- BIOLOGICAL Tabalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602224
The ClinicalTrials.gov registry entry for NCT01602224 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01602224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602224 about?
NCT01602224 is a clinical study titled "A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)". The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doc...
What is the current status of trial NCT01602224?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2012-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01602224?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Bortezomib (DRUG), Tabalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01602224?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.